Literature DB >> 7756587

Are cytotoxic agents beneficial in idiopathic membranous nephropathy? A meta-analysis of the controlled trials.

T F Imperiale1, S Goldfarb, J S Berns.   

Abstract

The use of cytotoxic agents for the treatment of idiopathic membranous nephropathy is controversial. Although several controlled trials have been published, both the comparison groups and the study findings have varied, resulting in clinical uncertainty. To explore this uncertainty, a meta-analysis of controlled trials of treatment with cyclophosphamide or chlorambucil was performed in patients with idiopathic membranous nephropathy and nephrotic-range proteinuria. Patients in the control groups received only symptomatic treatment or corticosteroids. Descriptive and quantitative data from each trial were abstracted independently. Outcomes included effects of treatment on renal function and proteinuria, with a complete remission (CR) or partial remission (PR) defined as the complete or partial resolution of proteinuria without deterioration of renal function. For patients having either any response (CR or PR) or only a CR, both the relative risk (RR) and the number needed to be treated were calculated. The five trials that satisfied criteria for inclusion in the analysis were clinically and statistically homogeneous. There were no placebo-controlled trials that met the criteria for inclusion. Among the 228 patients in these studies, the RR of achieving any response with cytotoxic agents was 2.3 (95% confidence interval, 1.7 to 3.2) and the RR for a CR was 4.6 (95% confidence interval, 2.2 to 9.3), with respective numbers needed to be treated of 2.9 and 4.7, meaning that between three and five patients would need to be treated with cytotoxic agents to achieve one response. Exclusion of the only nonrandomized trial had no significant effect on the results. Both chlorambucil and cyclophosphamide showed similar beneficial effects.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7756587     DOI: 10.1681/ASN.V581553

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  9 in total

1.  Evidence-based practice guideline for the treatment of CKD.

Authors: 
Journal:  Clin Exp Nephrol       Date:  2009-12       Impact factor: 2.801

2.  Treatment of progressive renal failure and nephrotic syndrome with azathioprine and prednisolone.

Authors:  L R Baker; B Tucker; I C Macdougall; R Oommen
Journal:  Postgrad Med J       Date:  1997-10       Impact factor: 2.401

Review 3.  Treatment of primary membranous nephropathy: where are we now?

Authors:  Andrea Angioi; Nicola Lepori; Ana Coloma López; Sanjeev Sethi; Fernando C Fervenza; Antonello Pani
Journal:  J Nephrol       Date:  2017-09-05       Impact factor: 3.902

Review 4.  Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.

Authors:  Thilo C von Groote; Gabrielle Williams; Eric H Au; Yizhi Chen; Anna T Mathew; Elisabeth M Hodson; David J Tunnicliffe
Journal:  Cochrane Database Syst Rev       Date:  2021-11-15

Review 5.  Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials.

Authors:  Yizhi Chen; Arrigo Schieppati; Guangyan Cai; Xiangmei Chen; Javier Zamora; Giovanni A Giuliano; Norbert Braun; Annalisa Perna
Journal:  Clin J Am Soc Nephrol       Date:  2013-02-28       Impact factor: 8.237

Review 6.  Idiopathic membranous nephropathy: management strategies.

Authors:  Marco Quaglia; Piero Stratta
Journal:  Drugs       Date:  2009-07-09       Impact factor: 9.546

Review 7.  Therapies for Membranous Nephropathy: A Tale From the Old and New Millennia.

Authors:  Francesco Scolari; Federico Alberici; Federica Mescia; Elisa Delbarba; Hernando Trujillo; Manuel Praga; Claudio Ponticelli
Journal:  Front Immunol       Date:  2022-03-01       Impact factor: 7.561

Review 8.  Membranous nephropathy in children: clinical presentation and therapeutic approach.

Authors:  Shina Menon; Rudolph P Valentini
Journal:  Pediatr Nephrol       Date:  2009-11-12       Impact factor: 3.714

9.  Chapter 7: Idiopathic membranous nephropathy.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.